CN1597952A - Nerve growth factor cDNA, clone and expresion of Chinese cobra - Google Patents
Nerve growth factor cDNA, clone and expresion of Chinese cobra Download PDFInfo
- Publication number
- CN1597952A CN1597952A CN 200410021513 CN200410021513A CN1597952A CN 1597952 A CN1597952 A CN 1597952A CN 200410021513 CN200410021513 CN 200410021513 CN 200410021513 A CN200410021513 A CN 200410021513A CN 1597952 A CN1597952 A CN 1597952A
- Authority
- CN
- China
- Prior art keywords
- growth factor
- nerve growth
- ngf
- cdna
- expression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002299 complementary DNA Substances 0.000 title claims abstract description 19
- 241000272144 Naja atra Species 0.000 title claims abstract description 17
- 108010025020 Nerve Growth Factor Proteins 0.000 title claims description 49
- 102000015336 Nerve Growth Factor Human genes 0.000 title claims description 49
- 229940053128 nerve growth factor Drugs 0.000 title claims description 43
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 33
- 239000008280 blood Substances 0.000 claims abstract description 15
- 210000004369 blood Anatomy 0.000 claims abstract description 15
- 238000000034 method Methods 0.000 claims abstract description 15
- 210000004907 gland Anatomy 0.000 claims abstract description 11
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 10
- 238000003757 reverse transcription PCR Methods 0.000 claims abstract description 9
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 8
- 231100000614 poison Toxicity 0.000 claims abstract description 6
- 239000002574 poison Substances 0.000 claims abstract description 6
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 16
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 13
- 230000008521 reorganization Effects 0.000 claims description 13
- 108090000790 Enzymes Proteins 0.000 claims description 10
- 102000004190 Enzymes Human genes 0.000 claims description 10
- 238000001962 electrophoresis Methods 0.000 claims description 10
- 239000013612 plasmid Substances 0.000 claims description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 9
- 241000235648 Pichia Species 0.000 claims description 9
- 239000012634 fragment Substances 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 6
- 241000588724 Escherichia coli Species 0.000 claims description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 6
- 230000001580 bacterial effect Effects 0.000 claims description 6
- 230000029087 digestion Effects 0.000 claims description 6
- 239000008103 glucose Substances 0.000 claims description 6
- 239000000047 product Substances 0.000 claims description 6
- 239000006228 supernatant Substances 0.000 claims description 6
- 229920000936 Agarose Polymers 0.000 claims description 4
- 101000577823 Naja atra Venom nerve growth factor Proteins 0.000 claims description 4
- 238000004520 electroporation Methods 0.000 claims description 4
- 238000000746 purification Methods 0.000 claims description 4
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 3
- 241001506991 Komagataella phaffii GS115 Species 0.000 claims description 3
- 102000006382 Ribonucleases Human genes 0.000 claims description 3
- 108010083644 Ribonucleases Proteins 0.000 claims description 3
- 238000001042 affinity chromatography Methods 0.000 claims description 3
- 125000000539 amino acid group Chemical group 0.000 claims description 3
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 3
- 239000001110 calcium chloride Substances 0.000 claims description 3
- 239000003153 chemical reaction reagent Substances 0.000 claims description 3
- 239000013613 expression plasmid Substances 0.000 claims description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 3
- 230000006698 induction Effects 0.000 claims description 3
- 230000001939 inductive effect Effects 0.000 claims description 3
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 229910052757 nitrogen Inorganic materials 0.000 claims description 3
- 239000002773 nucleotide Substances 0.000 claims description 3
- 125000003729 nucleotide group Chemical group 0.000 claims description 3
- 239000002244 precipitate Substances 0.000 claims description 3
- 230000001376 precipitating effect Effects 0.000 claims description 3
- 108091008146 restriction endonucleases Proteins 0.000 claims description 3
- 238000012216 screening Methods 0.000 claims description 3
- 238000012360 testing method Methods 0.000 claims description 3
- 238000005406 washing Methods 0.000 claims description 3
- 108700024394 Exon Proteins 0.000 claims description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims description 2
- 206010029240 Neuritis Diseases 0.000 abstract description 4
- 210000000496 pancreas Anatomy 0.000 abstract description 3
- 108091033319 polynucleotide Proteins 0.000 abstract description 2
- 239000002157 polynucleotide Substances 0.000 abstract description 2
- 102000040430 polynucleotide Human genes 0.000 abstract description 2
- 238000010839 reverse transcription Methods 0.000 abstract description 2
- 239000003102 growth factor Substances 0.000 abstract 4
- 230000007514 neuronal growth Effects 0.000 abstract 3
- 238000010367 cloning Methods 0.000 abstract 2
- 241000235058 Komagataella pastoris Species 0.000 abstract 1
- 206010036105 Polyneuropathy Diseases 0.000 abstract 1
- 230000007935 neutral effect Effects 0.000 abstract 1
- 230000002093 peripheral effect Effects 0.000 abstract 1
- 230000000144 pharmacologic effect Effects 0.000 abstract 1
- 208000019629 polyneuritis Diseases 0.000 abstract 1
- 235000018102 proteins Nutrition 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 3
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 3
- 230000001186 cumulative effect Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 201000001119 neuropathy Diseases 0.000 description 3
- 239000003998 snake venom Substances 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 description 2
- 238000013016 damping Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000036732 histological change Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 206010036631 Presenile dementia Diseases 0.000 description 1
- 101710141795 Ribonuclease inhibitor Proteins 0.000 description 1
- 229940122208 Ribonuclease inhibitor Drugs 0.000 description 1
- 102100037968 Ribonuclease inhibitor Human genes 0.000 description 1
- 241000270295 Serpentes Species 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 239000003637 basic solution Substances 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 210000002932 cholinergic neuron Anatomy 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 239000002642 cobra venom Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 210000004129 prosencephalon Anatomy 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000003161 ribonuclease inhibitor Substances 0.000 description 1
- 210000001044 sensory neuron Anatomy 0.000 description 1
- 210000001913 submandibular gland Anatomy 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
Landscapes
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004100215137A CN1316021C (en) | 2004-07-19 | 2004-07-19 | Nerve growth factor cDNA, clone and expresion of Chinese cobra |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004100215137A CN1316021C (en) | 2004-07-19 | 2004-07-19 | Nerve growth factor cDNA, clone and expresion of Chinese cobra |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1597952A true CN1597952A (en) | 2005-03-23 |
CN1316021C CN1316021C (en) | 2007-05-16 |
Family
ID=34663338
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2004100215137A Expired - Fee Related CN1316021C (en) | 2004-07-19 | 2004-07-19 | Nerve growth factor cDNA, clone and expresion of Chinese cobra |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1316021C (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102552881A (en) * | 2012-03-02 | 2012-07-11 | 广西医科大学 | Application of cobra venom nerve growth factor in preparing the medicine of preventing and treating liver fibrosis and liver cirrhosis |
CN102816766A (en) * | 2012-05-04 | 2012-12-12 | 沈阳医学院 | Method for screening snake venom nerve growth factor (vNGF) active polypeptides |
CN103159843A (en) * | 2011-12-19 | 2013-06-19 | 中国科学院生物物理研究所 | Preparation method and drug application value of nerve growth factor mutant with low immunization side effects |
CN106939041A (en) * | 2017-04-14 | 2017-07-11 | 奔驰生物科技(云南)有限公司 | The method that Recombinant Naja naja atra NGF is purified using polyclonal antibody affinity column |
EP4115898A4 (en) * | 2019-11-16 | 2023-11-15 | Qi, Zhankai | Use of group of snake nerve growth factors and snake nerve growth factor precursors in treatment of senile dementia |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5229365A (en) * | 1991-05-15 | 1993-07-20 | President And Fellows Of Harvard College | Endocrine cell stimulation by neurotrophic agents |
CN1074448A (en) * | 1992-09-29 | 1993-07-21 | 中国医科大学 | The method of separation and purification of nerve growth factor from snake venom |
CN1246483A (en) * | 1998-08-28 | 2000-03-08 | 大连卫康生物科技开发有限公司 | Process for extracting nerve growth factor from poisonous snake |
-
2004
- 2004-07-19 CN CNB2004100215137A patent/CN1316021C/en not_active Expired - Fee Related
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103159843A (en) * | 2011-12-19 | 2013-06-19 | 中国科学院生物物理研究所 | Preparation method and drug application value of nerve growth factor mutant with low immunization side effects |
CN103159843B (en) * | 2011-12-19 | 2014-11-05 | 中国科学院生物物理研究所 | Preparation method and drug application value of nerve growth factor mutant with low immunization side effects |
CN102552881A (en) * | 2012-03-02 | 2012-07-11 | 广西医科大学 | Application of cobra venom nerve growth factor in preparing the medicine of preventing and treating liver fibrosis and liver cirrhosis |
CN102816766A (en) * | 2012-05-04 | 2012-12-12 | 沈阳医学院 | Method for screening snake venom nerve growth factor (vNGF) active polypeptides |
CN106939041A (en) * | 2017-04-14 | 2017-07-11 | 奔驰生物科技(云南)有限公司 | The method that Recombinant Naja naja atra NGF is purified using polyclonal antibody affinity column |
CN106939041B (en) * | 2017-04-14 | 2020-10-16 | 奔驰生物科技(云南)有限公司 | Method for purifying cobra venom nerve growth factor by using polyclonal antibody affinity column |
EP4115898A4 (en) * | 2019-11-16 | 2023-11-15 | Qi, Zhankai | Use of group of snake nerve growth factors and snake nerve growth factor precursors in treatment of senile dementia |
Also Published As
Publication number | Publication date |
---|---|
CN1316021C (en) | 2007-05-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1320117C (en) | Adiponectin-Glucagon-like peptide-1-like peptide recombinant protein expression vector and construction | |
CN1597952A (en) | Nerve growth factor cDNA, clone and expresion of Chinese cobra | |
CN1177055C (en) | Antibacterial peptide gene of fly and its cloning process | |
CN100344758C (en) | Antibacterial peptide gene of Chinese prawn containing single whey acidic protein structure domain and its coded antibacterial peptide and application | |
CN113604556A (en) | Gene SNP detection kit for determining therapeutic effect correlation of GLP-1 receptor agonist | |
CN1534097A (en) | Chinese prawn heat shock protein 70 gene and its clone method | |
CN1157406C (en) | Novel, ATP-sensitive potassium-channel proteins and genes for the same | |
CN1262559C (en) | Housefly phylaxin gene, and its cloning method and recombinant application | |
CN1257987C (en) | Molecule labelling method for specific PCR detection of genes related to chicken growth and egg-laying deseription by employing allelomorph and use thereof | |
CN110157798A (en) | A kind of primer combination of probe instructing diabetic individual medication gene loci polymorphism and its application and kit | |
CN1381587A (en) | Antibacterial peptide gene of Chinese prawn and its colon technique | |
CN1167799C (en) | Method for secreting and expressing acid fibroblast growth factor | |
CN1781943A (en) | South China sea conus littertus linnaeus nervotoxin and its coding sequence and use | |
CN1176946C (en) | New-type alpha-interferon | |
CN1113963C (en) | Preparation and application of rhBTR gene and gene probe | |
CN105002184B (en) | A kind of application of the germline SCN11A genes in diagnosing chip is prepared that make a variation | |
CN1072720C (en) | Chicken growth hormone gene and an expression thereof in E.coli | |
CN1199993C (en) | N-terminal deletion lipocyte complement related protein and its preparation method | |
CN114457085A (en) | Scylla paramamosain cap 'n' collar gene and application thereof in preparation of pathological detection diagnostic reagent | |
CN1425677A (en) | New gene SNX21 of human SNX family | |
CN1632118A (en) | Biology function of human nervous specific expression gene BRI3 | |
CN1343773A (en) | Brachydactyly and body height associated gene | |
CN1364812A (en) | Human glial cell derived neurotrophic factor and its derivatives and use | |
CN110846317A (en) | Detection method of circular RNA and application of circular RNA in adult neural stem cell identification | |
CN1254540C (en) | Cloning and expression of Baimei pit viper Aidingbit CDNA for treating tumor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: ZHAO BAOCHANG Effective date: 20050701 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20050701 Address after: 116600 No. 148 west the Yellow Sea Road, Dalian Development Zone, Liaoning Applicant after: Hao Wenxue Co-applicant after: Zhao Baochang Address before: 116600 No. 148 west the Yellow Sea Road, Dalian Development Zone, Liaoning Applicant before: Hao Wenxue |
|
ASS | Succession or assignment of patent right |
Owner name: ZHAO BAOCHANG TIAN XIAOGUANG TIAN AIPING Free format text: FORMER OWNER: ZHAO BAOCHANG Effective date: 20050805 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20050805 Address after: 116600 No. 148 west the Yellow Sea Road, Dalian Development Zone, Liaoning Applicant after: Hao Wenxue Co-applicant after: Zhao Baochang Co-applicant after: Tian Xiaoguang Co-applicant after: Tian Aiping Address before: 116600 No. 148 west the Yellow Sea Road, Dalian Development Zone, Liaoning Applicant before: Hao Wenxue Co-applicant before: Zhao Baochang |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C19 | Lapse of patent right due to non-payment of the annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |